The growing potential of immunotherapy for the treatment of cancer and inflammatory disorders highlights the need for experimental models that enable the evaluation of therapeutic efficacy, optimization through combination strategies, and assessment of potential toxicities. One promising approach involves using models that express human immunotherapy targets or incorporate components of the human hematopoietic or immune system. These models allow the testing of human-specific compounds without the need to develop mouse-specific surrogates.
Humanized mouse models are increasingly employed in this context. These models are modified through genetic humanization (e.g. gene replacement), cellular humanization (e.g. engraftment with human cells), or a combination of both. In this presentation, we will explore these expanding families of humanized mouse models and discuss their respective advantages and limitations, illustrated through case studies.
Have questions or want to find out more?
Nicolas Legrand, PhD
Head of Translational Pharmacology
Nicolas Legrand is the head of translational pharmacology at the Oncodesign Services-ZoBio Group, where he currently leads a team of over 40 project leads and technical staff. His department provides expertise in combining in vitro and in vivo capabilities in a variety of therapeutic areas for biochemical & cellular assays, acute and chronic inflammation (skin, lung, gut, liver, kidney, systemic, autoimmune), infectious diseases (including COVID), pharmacokinetics, oncology and immuno-oncology. Nicolas has a PhD in Immunology from the Pierre and Marie Curie University.
